Singer MA, et al. - Researchers conducted the study for analyzing the impact of diabetic macular edema (DME) control with the 0.2 µg/day fluocinolone acetonide (FAc) intravitreal implant on quality of life (QOL) outcomes. Post-hoc analysis of patients from the FAME study who obtained the FAc implant and responded to the National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ-25) at baseline and Year 3 (N = 324). The data presented in this work showed a positive and sustained relationship between the long-term control of DME and patient-reported QOL outcomes for up to 3 years following a single FAc implant in patients with controlled DME.